Hypersensitivity reactions and anaphylaxis to checkpoint inhibitor–monoclonal antibodies and desensitization

ObjectiveTo review type 1 hypersensitivity reactions and anaphylaxis to checkpoint inhibitor–monoclonal antibodies its management with drug desensitization.Data SourcesEnglish-language literature on MEDLINE regarding hypersensitivity, anaphylaxis, antibodies.Study SelectionsReferences were selected based relevance, novelty, robustness, applicability.ResultsThere are well-known tissue toxicities associated inhibitors, but have been underreported. The presentation of these is clinical phenotypes underlying endotypes identified by specific biomarkers. Drug desensitizations successfully applied inhibitor drugs allow patients cancer receive first-line therapies. This provides current best practices for the recognition diagnosis inhibitors their using desensitization.ConclusionHypersensitivity as potential adverse effects induced antibodies. desensitization a safe effective treatment option who experience in need monoclonal improve outcomes.